Everett Harris & Co. CA Cuts Position in Zoetis Inc. (NYSE:ZTS)

Everett Harris & Co. CA lessened its holdings in Zoetis Inc. (NYSE:ZTS) by 6.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,803 shares of the company’s stock after selling 306 shares during the period. Everett Harris & Co. CA’s holdings in Zoetis were worth $948,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Cary Street Partners Investment Advisory LLC increased its stake in shares of Zoetis by 7.4% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 93,735 shares of the company’s stock valued at $16,308,000 after purchasing an additional 6,457 shares in the last quarter. Peak Financial Advisors LLC purchased a new stake in Zoetis during the 4th quarter worth approximately $2,776,000. BLB&B Advisors LLC increased its stake in Zoetis by 1.9% during the 3rd quarter. BLB&B Advisors LLC now owns 60,872 shares of the company’s stock worth $10,591,000 after buying an additional 1,107 shares in the last quarter. Ronald Blue Trust Inc. increased its stake in Zoetis by 5.4% during the 3rd quarter. Ronald Blue Trust Inc. now owns 6,216 shares of the company’s stock worth $1,070,000 after buying an additional 317 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. increased its stake in Zoetis by 10.9% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 183,564 shares of the company’s stock worth $36,230,000 after buying an additional 17,976 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

ZTS has been the subject of several research reports. Piper Sandler boosted their price objective on Zoetis from $215.00 to $220.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 20th. Barclays upped their price target on Zoetis from $255.00 to $260.00 and gave the company an “overweight” rating in a research report on Wednesday, February 14th. The Goldman Sachs Group upped their price target on Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research report on Wednesday, January 17th. BNP Paribas began coverage on Zoetis in a research report on Thursday, December 7th. They issued an “outperform” rating and a $237.00 price target for the company. Finally, Jefferies Financial Group restated a “buy” rating and issued a $230.00 price target on shares of Zoetis in a research report on Tuesday, December 19th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Zoetis currently has an average rating of “Buy” and a consensus target price of $224.33.

Zoetis Trading Up 0.4 %

NYSE:ZTS traded up $0.61 during trading hours on Thursday, reaching $169.12. 3,395,584 shares of the stock were exchanged, compared to its average volume of 2,739,733. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. The business has a 50-day moving average of $185.92 and a two-hundred day moving average of $182.24. Zoetis Inc. has a twelve month low of $151.03 and a twelve month high of $201.92. The company has a market capitalization of $77.43 billion, a price-to-earnings ratio of 33.36, a PEG ratio of 2.53 and a beta of 0.87.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The firm had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. During the same quarter last year, the company earned $1.15 earnings per share. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. On average, equities analysts predict that Zoetis Inc. will post 5.8 EPS for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be given a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.02%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s dividend payout ratio is currently 34.12%.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of the company’s stock in a transaction on Thursday, January 18th. The stock was sold at an average price of $191.43, for a total transaction of $176,689.89. Following the sale, the executive vice president now owns 17,569 shares of the company’s stock, valued at $3,363,233.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 2,209 shares of company stock valued at $408,453. 0.12% of the stock is currently owned by company insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.